Subcuject ApS
Nøgletal
- Afkastningsgrad
- 3,9 %
- Egenkapitalforrentning
- –
- Likviditetsgrad
- 233,5 %
- Soliditetsgrad
- -115,1 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | 2.553.753 |
Driftsresultat | 148.589 |
Finansielle indtægter | 1.155 |
Finansielle omkostninger | 501.246 |
Skat af årets resultat | -77.330 |
Årets resultat | -274.172 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 2 |
Personaleomkostninger | 2.405.164 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 1.562.605 |
Kortfristede aktiver | 3.783.867 |
Aktiver i alt | 3.783.867 |
Egenkapital | -4.356.525 |
Forpligtelser i alt | 8.140.392 |
Kortfristede forpligtelser | 1.620.458 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Andre kortfristede tilgodehavender | 2.130.401 |
Leverandørgæld | 323.595 |
Anden kortfristet gæld | 1.287.021 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 227.207 |
Overført resultat | -4.583.732 |
Højdepunkter fra årsrapporten
Forretning og udvikling
The primary objective of the company is development and commercialization of innovative, proprietary, wearable medical devices for subcutaneous bolus injection of larger volume pharmaceuticals. One product is a wearable bolus injector (WBI) based on osmosis as the driving force without any electromechanical components. It is intended as a very easy to use wearable injection device and with the low complexity and it will have a very low manufacturing cost compared with electromechanical products. Another products is a wearable autoinjector based on a number components shared with the WBI and driven by a spring. The injectors are to be prefilled with therelevant drug and the company's business model, therefore, requires collaboration with pharmaceutical companies.
The income statement of the Company for 2022 shows a loss of DKK 274,172, and at 31 December 2022 the balance sheet of the Company shows negative equity of DKK 4,356,525. The loss is a result of the company being in the development phase and is according to plan and the negative equity is a result of long term loans. During 2022, the product technology was significantly further proven. Subcuject are seeing a good interest in the injection device from a number of major pharmaceutical companies Subsequent events No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.
Risici og væsentlige forhold
In 2022 the Company entered into an agreement with a partner regarding financing until August 2023. The continued operations and development of the research project is dependent on an extension of the agreement or that alternative financing is established. If the agreement is not extended, the company's current cash flow budget show that the Company will not be able to continue its operations after August 2023.The Company has prepared the annual report under the going concern assumption, but based on the above, there exists a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.It is Management's expectations that the partner will extend the financing, which is why the annual report has been prepared under the going concern assumption.
Forpligtelser og sikkerhedsstillelser
The company has a tenancy commitment with a notice period as of 3 months 23,127 22,611
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger